[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 207,176,000
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 46,792 M
  • Annual Income, $ 15,509 M
  • EBIT $ 23,190 M
  • EBITDA $ 26,518 M
  • 60-Month Beta 0.77
  • Price/Sales 4.40
  • Price/Cash Flow 9.83
  • Price/Book 6.47

Options Overview Details

View History
  • Implied Volatility 38.98% (-1.26%)
  • Historical Volatility 32.71%
  • IV Percentile 10%
  • IV Rank 12.18%
  • IV High 64.20% on 10/09/25
  • IV Low 35.49% on 12/31/25
  • Expected Move (DTE 3) 1.29 (2.75%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 43,278
  • Volume Avg (30-Day) 88,486
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 1,510,947
  • Open Int (30-Day) 1,499,286
  • Expected Range 45.71 to 48.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.83
  • Number of Estimates 5
  • High Estimate $0.90
  • Low Estimate $0.77
  • Prior Year $0.97
  • Growth Rate Est. (year over year) -14.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.95 +27.20%
on 04/13/26
47.79 -1.65%
on 05/11/26
+9.48 (+25.27%)
since 04/10/26
3-Month
35.12 +33.83%
on 03/30/26
49.85 -5.72%
on 02/17/26
-1.93 (-3.94%)
since 02/12/26
52-Week
35.12 +33.83%
on 03/30/26
81.44 -42.29%
on 06/13/25
-20.74 (-30.62%)
since 05/12/25

Most Recent Stories

More News
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

BPC.CN : 0.4950 (+7.61%)
PNGAF : 0.3650 (+9.02%)
NVO : 47.00 (+1.29%)
HIMS : 25.03 (-14.10%)
LLY : 989.87 (+2.37%)
PFE : 25.87 (+0.23%)
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary -- Investor interest in the next-generation wellness market is picking up fast as peptide-based health and performance...

BPC.CN : 0.4950 (+7.61%)
PNGAF : 0.3650 (+9.02%)
NVO : 47.00 (+1.29%)
HIMS : 25.03 (-14.10%)
LLY : 989.87 (+2.37%)
PFE : 25.87 (+0.23%)
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus

As Hims & Hers pivots to branded GLP-1s via a Novo Nordisk deal, all eyes are on the company’s May 11 earnings as investors look for sustained subscriber growth.

HIMS : 25.03 (-14.10%)
NVO : 47.00 (+1.29%)
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

NVO : 47.00 (+1.29%)
LLY : 989.87 (+2.37%)
Biotech’s Next Wave May Already be in Motion

DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction,...

NTHI : 5.51 (+0.18%)
NVO : 47.00 (+1.29%)
LLY : 989.87 (+2.37%)
REGN : 723.41 (+1.49%)
Novo Nordisk Reports Earnings While Trading Like the Obesity Boom Already Ended

Barchart Research What to Expect from NVO Earnings NVO Generated May 5, 2026 Current Price $44.87 EPS Estimate $$0.87 Consensus Rating Hold Average Move 4.47% Novo Nordisk Reports Earnings While Trading...

NVO : 47.00 (+1.29%)
Jobs Figures Roll in Friday in Canada

Monday U.S. Featured Earnings Palantir Technologies Inc. (NASDAQ: PLTR) (Q1) EPS ...

ANET : 142.54 (+4.48%)
NVO : 47.00 (+1.29%)
VRTX : 448.29 (+3.01%)
SATS : 129.38 (+0.19%)
WMB : 74.73 (+0.74%)
HSBC : 89.97 (-0.64%)
DIS : 106.16 (+1.38%)
MCD : 274.84 (+0.09%)
PAA : 21.94 (-0.23%)
UI : 703.49 (-4.75%)
AMD : 448.29 (-2.29%)
SHEL : 85.35 (-0.01%)
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

NVO : 47.00 (+1.29%)
LLY : 989.87 (+2.37%)
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

Viking Therapeutics stock faces near-term pressure, but its GLP-1 pipeline and clinical timeline could deliver significant long-term upside

VKTX : 31.32 (-1.26%)
NVO : 47.00 (+1.29%)
LLY : 989.87 (+2.37%)
Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means

Amazon is stepping into the GLP-1 arena, with the consumer giant positioning itself as a competitor to Hims & Hers Health. Hims may have a problem on its hands.

HIMS : 25.03 (-14.10%)
NVO : 47.00 (+1.29%)
LLY : 989.87 (+2.37%)
AMZN : 265.82 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 48.13
2nd Resistance Point 47.62
1st Resistance Point 47.31
Last Price 47.00
1st Support Level 46.49
2nd Support Level 45.98
3rd Support Level 45.67

See More

52-Week High 81.44
Fibonacci 61.8% 63.75
Fibonacci 50% 58.28
Fibonacci 38.2% 52.81
Last Price 47.00
52-Week Low 35.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.